Beyond the lessons learned from the COVID-19 pandemic: opportunities to optimize clinical trial implementation in oncology

Affiliations

• ¹ Scientific and Medical Division, European Society for Medical Oncology (ESMO), Lugano, Switzerland.
• ² Head of the Oncology Medicine Department, Institut Jules Bordet, Université libre de Bruxelles, Belgium.
• ³ Scientific and Medical Division, European Society for Medical Oncology (ESMO), Lugano, Switzerland. Electronic address: george.pentheroudakis@esmo.org.
• ⁴ Department of Oncology, Clinica Universidad de Navarra, Pamplona, Spain.
• ⁵ Vall d'Hebron Institute of Oncology (VHIO) and Vall d'Hebron University Hospital, Barcelona, Spain.
• ⁶ Istituto Europeo di Oncologia, IRCCS and University of Milano, Milano, Italy.
• ⁷ The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London.
• ⁸ The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, UK.
• ⁹ Department of Oncology, Gastroenterology, Hepatology, Pulmonology, and Infectious Diseases, University Cancer Center Leipzig (UCCL), Leipzig University Medical Center, Leipzig, Germany.
• ¹⁰ Hospital Clinic Universitario, Biomedical Research institute INCLIVA, University of Valencia, Valencia, Spain.
• ¹¹ Vall d'Hebron Hospital Campus and Institute of Oncology (VHIO), UVic-UCC, Barcelona, Spain.
• ¹² Oncology Department - CHUV, Lausanne University, Lausanne, Switzerland.